Lonza Group AG (LZAGY)

Compare

59.17

-1.32

(-2.18%)

As of 11:59:50 AM EST. Market Open.

Synaffix secures ADC deals with Boehringer and Mitsubishi Tanabe

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Pharmaceutical Technology 3 days ago

LZAGY
-2.18%
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology

Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer has licensed Synaffix's ADC technology. This new partnership significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company's aim of transforming the lives of people with cancer.

PR Newswire 4 days ago

LZAGF
-3.27%
LZAGY
-2.18%
Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology

Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced that it has licensed its ADC technology to Mitsubishi Tanabe Pharma Corporation ("MTPC"), the pharma arm of Mitsubishi Chemical Group ("MCG").

PR Newswire 4 days ago

LZAGF
-3.27%
LZAGY
-2.18%
NVST or LZAGY: Which Is the Better Value Stock Right Now?

NVST vs. LZAGY: Which Stock Is the Better Value Option?

Zacks 12 days ago

LZAGY
-2.18%
NVST
New Strong Sell Stocks for December 23rd

CENTA, IDEXY and LZAGY have been added to the Zacks Rank #5 (Strong Sell) List on December 23, 2024.

Zacks 21 days ago

CENTA

LZAGY
-2.18%
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO

Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal. Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi.

BioPharma Dive last month

LZAGY
-2.18%
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has entered into a licensing agreement with Elevation Oncology, Inc., an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.

PR Newswire last month

LZAGF
-3.27%
LZAGY
-2.18%
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.

PR Newswire last month

LZAGF
-3.27%
LZAGY
-2.18%
ELEV
Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced that it has licensed its ADC technology to BigHat Biosciences, Inc. ("BigHat"). BigHat will combine Synaffix technology with its world-class ML antibody design platform for the development of a new ADC pipeline program.

PR Newswire 2 months ago

LZAGF
-3.27%
LZAGY
-2.18%
Lonza Group AG (LZAGY): Among UBS’ Top Tech Based Disruptive Stocks For 2030

We recently compiled a list of the UBS’ Top Tech Based Disruptive Stocks For 2030: Top 29 Stocks. In this article, we are going to take a look at where Lonza Group AG (OTC:LZAGY) stands against the other tech based disruptive stocks. When it comes to investing and making massive gains on the stock market, disruption […]

Insider Monkey 2 months ago

LZAGY
-2.18%
AHCO or LZAGY: Which Is the Better Value Stock Right Now?

AHCO vs. LZAGY: Which Stock Is the Better Value Option?

Zacks 2 months ago

LZAGY
-2.18%
AHCO
Lonza Expects Accelerating Sales Growth in Final Quarter

The Swiss life-sciences company said it expected accelerated sales growth in the fourth quarter on the back of the timing of product releases and the ramp-up of its new acquired manufacturing facility, and confirmed its guidance for the full year.

The Wall Street Journal 2 months ago

LZAGF
-3.27%
LZAGY
-2.18%
AHCO vs. LZAGY: Which Stock Is the Better Value Option?

AHCO vs. LZAGY: Which Stock Is the Better Value Option?

Zacks 3 months ago

LZAGY
-2.18%
AHCO
All You Need to Know About Lonza Group (LZAGY) Rating Upgrade to Strong Buy

Lonza Group (LZAGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 4 months ago

LZAGY
-2.18%
ESLOY or LZAGY: Which Is the Better Value Stock Right Now?

ESLOY vs. LZAGY: Which Stock Is the Better Value Option?

Zacks 5 months ago

LZAGY
-2.18%
ESLOY
-0.91%
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

Explore key insights from Acumen Pharmaceuticals' Q1 2024 earnings, focusing on their innovative Alzheimer's treatments and financial outlook.

GuruFocus.com 7 months ago

ABOS

LZAGY
-2.18%
Maravai LifeSciences Holdings Inc (MRVI) (Q1 2024) Earnings Call Transcript Highlights: ...

Despite a net loss, MRVI showcases strategic expansions and robust partnerships, setting the stage for future growth.

GuruFocus.com 8 months ago

MRVI

LZAGY
-2.18%
NeuroSense Announces First Quarter 2024 Business Update

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.

PR Newswire 8 months ago

LZAGF
-3.27%
LZAGY
-2.18%
NRSN
Lonza Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Lonza Group ( VTX:LONN ) Full Year 2023 Results Key Financial Results Revenue: CHF6.72b (up 7.9% from FY 2022). Net...

Simply Wall St. 9 months ago

LZAGY
-2.18%
Lonza Group AG's (VTX:LONN) largest shareholders are individual investors with 56% ownership, institutions own 44%

Key Insights The considerable ownership by individual investors in Lonza Group indicates that they collectively have a...

Simply Wall St. 9 months ago

LZAGY
-2.18%

Performance Overview

Return	LZAGY	MSCI WORLD
YTD	-0.25%	-1.40%
1-Year	+37.83%	+15.74%
3-Year	-19.12%	+14.08%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lonza Group AG (LZAGY)

Synaffix secures ADC deals with Boehringer and Mitsubishi Tanabe

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology

Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology

NVST or LZAGY: Which Is the Better Value Stock Right Now?

New Strong Sell Stocks for December 23rd

Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

Lonza Group AG (LZAGY): Among UBS’ Top Tech Based Disruptive Stocks For 2030

AHCO or LZAGY: Which Is the Better Value Stock Right Now?

Lonza Expects Accelerating Sales Growth in Final Quarter

AHCO vs. LZAGY: Which Stock Is the Better Value Option?

All You Need to Know About Lonza Group (LZAGY) Rating Upgrade to Strong Buy

ESLOY or LZAGY: Which Is the Better Value Stock Right Now?

Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

Maravai LifeSciences Holdings Inc (MRVI) (Q1 2024) Earnings Call Transcript Highlights: ...

NeuroSense Announces First Quarter 2024 Business Update

Lonza Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Lonza Group AG's (VTX:LONN) largest shareholders are individual investors with 56% ownership, institutions own 44%

Performance Overview